Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This study will compare the relative bioavailability (rate and extent of absorption) of 3 mg
Alprazolam Extended Release Tablets manufactured and distributed by TEVA Pharmaceuticals USA
with that of 3 mg XANAX XR® Tablets by Pharmacia & Upjohn Company following a single oral
dose (1 x 3 mg extended release tablet) in healthy adult subjects administered under
non-fasting conditions.